Belite Bio, Inc. has priced an underwritten public offering of 2,272,727 American Depositary Shares at $154.00 per ADS, expected to raise approximately $350.0 million. The net proceeds will be used for commercialization preparation, pipeline development, and general corporate purposes. The offering is expected to close on December 3, 2025. The lead managers for the offering are Morgan Stanley & Co. LLC, Leerink Partners, BofA Securities, and Cantor. Belite Bio is a clinical-stage drug development company focusing on degenerative retinal diseases and has a lead candidate, Tinlarebant, currently in clinical trials for STGD1 and GA.

Read more at GlobeNewswire: Belite Bio Announces Pricing of $350.0 Million Underwritten